id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-328074-pcvdr052	Fuereder, Thorsten	Circumnavigating the challenges of COVID-19 in oncology	2020-05-07		.txt	text/plain	1842	83	40	authors: Fuereder, Thorsten; Gunsilius, Eberhard; Bartsch, Rupert; Hilbe, Wolfgang At this time, patients with haematological malignancies may well be the most threatened patient population as many are heavily immunosuppressed due to the underlying disease, their treatment, or both, and thus are highly susceptible to severe complications if infected with SARS CoV-2. The European Society of Medical Oncology (ESMO) has meanwhile provided comprehensive guidelines for the management and treatment of lung cancer patients in the SARS CoV-2 era [6] : High priority in stage IV lung cancer remains the initiation of firstor second-line chemotherapy, immunotherapy or TKI therapy. Based on these findings the interleukin-6 inhibitor tocilizumab, which is used for the treatment of severe CPI (and CAR-T cells) induced adverse events, is currently being evaluated in clinical trials in patients with COVID-19. Therefore, no recommendations can be given to delay CPI therapy for cancer patients during the SARS CoV-2 pandemic [7] .	./cache/cord-328074-pcvdr052.txt	./txt/cord-328074-pcvdr052.txt